Drug Profile
XP 105
Alternative Names: BI-860585; XP-105Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim Pharmaceuticals; Evotec AG
- Developer Boehringer Ingelheim Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium (PO)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Italy (PO)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Belgium (PO)